Cell and gene therapy

The cell and gene market is thriving with innovation, investment, partnerships, and M&A activity. But much remains unclear about how these therapies can deliver full value, and where pharma and biotech leaders should invest energy and resources to get these transformational therapies in patients’ hands.

Working together

We partner with cell and gene therapy manufacturers, technology providers, pharma, and biotechs to determine the most effective strategies for maximising the potential of these groundbreaking treatments.

Working at the intersection of technology, science, innovation, strategy, and healthcare, we understand the factors influencing value delivery and are here to help you navigate the complexity of evolving regulatory frameworks and rapid scientific advancements.

Together, we will realise the promise of cell and gene therapies and create lasting impact that transforms the future of medicine and patient care.

Talk to us about

Equipment and consumable development

Developing new and innovative technologies to improve CGT manufacturing, from new bioreactors to sensors to consumables and more.

Technology strategy and market insights

For existing and new players in the CGT space to understand, assess and leverage new technologies and technology partners to grow in the CGT market.

Manufacturing process development

Supporting therapy manufacturers with the improvement of their CGT manufacturing processes, from technology selection to demand and capacity modelling to facility strategy.

Sustainability

Designing for sustainability and circularity, and supporting industries in their material and waste strategies.

Featured insight

Medical researcher working in laboratory

Report

Expert views

Focus is usually key in bringing new products and services to market in highly innovative sectors. However, to mitigate risk in a highly uncertain market, established pharma and biotech companies developing biotherapeutics should look at diversifying their portfolio through the development and/or acquisition of multiple CGT platforms across different therapeutic areas.”

Paolo Siciliano Cell and gene therapy

Read the article

We believe scaling manufacturing, improving market access, patient centricity and leveraging innovative technologies for the pre-clinical and clinical settings are the four key areas to improving accessibility to CGTs.”

Anu Solanki Technology

Read the article

Understanding the nature of the new biotherapeutics developed and how they are delivered is vital for CGT manufacturers, healthcare professionals, and patients to enable a facilitated clinical application while reducing the overall costs of these transformative therapies.”

Maria Aspioti Life sciences

Read the article

To support the successful delivery of an increasing number of therapies to patients, it is critical to leverage digital tools and experiences across development phases and among the various stakeholders.”

Gloria Lam Cell and gene therapy

Read the article